Raymond James upgraded ProQR Therapeutics (PRQR) to Strong Buy from Outperform with a price target of $14, up from $6. The firm cites the recent successful clinical translation of RNA editing for the upgrade. The analyst has “even higher conviction now” in clinical translation of ProQR’s lead program AX-0810, which edits NTCP for treatment of cholestatic diseases. Raymond James notes that ProQR expects to provide additional preclinical data for AX-0810 related to the selected candidate and its delivery modality as well as pre-clinical data for AX-1412 in cardiovascular disease by the end of 2024.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRQR: